Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

This publication has 28 references indexed in Scilit:

• Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
  Circulation, 2004
• Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects
  Circulation, 2004
• Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
  Journal of the American College of Cardiology, 2004
• Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis
  The American Journal of Cardiology, 2002
• The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
  Arthritis Care & Research, 2002
• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations
  Journal of the American College of Cardiology, 1999
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
  BMJ, 1994
• Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
  Published by Elsevier ,1990